Evidence-based Medicine
5 ways to spot if someone is trying to mislead you when it comes to science
16 Mar, 2021 | 01:41h | UTC5 ways to spot if someone is trying to mislead you when it comes to science – The Conversation
Commentary on Twitter
Solid list! "5 ways to spot if someone is trying to mislead you when it comes to science" https://t.co/AnFZtWuUBc via @ConversationEDU
1. The ‘us versus them’ narrative
2. ‘I’m not a scientist, but…’
3. Ref to ‘science not being settled’
4. Overly simplistic
5. Cherry-picking— Timothy Caulfield (@CaulfieldTim) March 14, 2021
Update on the safety of COVID-19 Vaccine AstraZeneca
16 Mar, 2021 | 02:35h | UTCUpdate on the safety of COVID-19 Vaccine AstraZeneca
Related: Countries should continue AstraZeneca rollout: WHO – MedicalXpress AND Expert reaction to news that Germany has halted vaccinations with the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca finds no evidence of increased blood clot risk from vaccine – Reuters AND Data suggest no increased risk of blood clots from the AstraZeneca vaccine. Australia shouldn’t pause its rollout – The Conversation
Commentary on Twitter
As of March 8th, Around 17 million people in the EU & UK received the vaccine , there have been 15 events of DVT & 22 events of pulmonary embolism reported among those given the vaccine,This is much lower than would be expected to occur naturally in a general population
Please RT https://t.co/tnn4brxwpp— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) March 14, 2021
Colchicine and COVID-19: a Tale of Two Trials
9 Mar, 2021 | 02:51h | UTCColchicine and COVID-19: a Tale of Two Trials – CVCT CardioBrief
Study 1: RECOVERY trial: Colchicine arm stopped for lack of efficacy in patients hospitalized with COVID-19
Study 2: [Preprint] Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19
[Medicine based on data leaks…] Oxford study indicates AstraZeneca vaccine is effective against SARS-CoV-2 Lineage P.1
7 Mar, 2021 | 19:48h | UTC
Commentary on Twitter
https://twitter.com/hildabast/status/1368010132781600773
Treatment effects in randomized trials using routinely collected data for outcome assessment versus traditional trials: meta-research study
7 Mar, 2021 | 19:18h | UTC
Quantitatively evaluating the cross-sectoral and One Health impact of interventions: A scoping review and case study of antimicrobial resistance
7 Mar, 2021 | 19:10h | UTCInfographic: Economic evaluations of One-Health interventions: an antimicrobial resistance case study
Commentary on Twitter
An exciting paper by @nichola_naylor sets out a new way to quantitatively evaluate the #OneHealth impact of interventions, using #AMR as a case study.
Read the full paper ➡️ https://t.co/IPVoa0lTMh
Download our infographic ➡️ https://t.co/vjtjgwkkOX pic.twitter.com/lzAqbcWern— LSHTM AMR Centre (@LSHTM_AMR) March 1, 2021
Opinion | COVID vaccination studies: plan now to pool data, or be bogged down in confusion
4 Mar, 2021 | 08:48h | UTCCOVID vaccination studies: plan now to pool data, or be bogged down in confusion – Nature
Scientists want virtual meetings to stay after the COVID pandemic
4 Mar, 2021 | 08:47h | UTCScientists want virtual meetings to stay after the COVID pandemic – Nature
Why clinicians should know about Mendelian randomization
4 Mar, 2021 | 08:17h | UTCWhy clinicians should know about Mendelian randomization – Rheumatology
COVID-19 research in critical care: the good, the bad, and the ugly
3 Mar, 2021 | 08:49h | UTCCOVID-19 research in critical care: the good, the bad, and the ugly – Intensive Care Medicine
Commentary on Twitter
Challenges, achievements, directions of critical care research in #pandemic, from early small #COVID19 studies (incomplete/inconsistent data), to large-scale registries, through overlapping/competing & underpowered trials, often with poor LMIC involvement.https://t.co/EyEui4pKPi pic.twitter.com/jUDXAVaD5z
— Intensive Care Medicine (@yourICM) March 1, 2021
Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial
3 Mar, 2021 | 08:36h | UTC
Commentary on Twitter
I love this paper on Bayes.
Aren’t trials just like medical tests: they update our prior knowledge or beliefs?
If you can discuss a trial using its p-wave or confidence intervals, why not its posterior probabilities given *justified* priors.
(Yes, I am enthralled!) https://t.co/w1ym9jgQD5
— John Mandrola, MD (@drjohnm) March 1, 2021
The $450 question: Should journals pay peer reviewers?
3 Mar, 2021 | 08:33h | UTCThe $450 question: Should journals pay peer reviewers? – Science
Related: Richard Smith: Peer reviewers—time for mass rebellion? – The BMJ Opinion AND 5 Things We Learned About Peer Review in 2020 – Absolutely Maybe
To beta-amyloid or not to beta-amyloid? An innovative meta-analysis offers new insight into Alzheimer’s drugs
2 Mar, 2021 | 01:18h | UTCOriginal study: Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis – The BMJ
Commentary on Twitter
https://twitter.com/artwalaszek/status/1365098101845987328
Series of n-of-1 trials show no difference in muscle symptoms in patients receiving placebo or statins
25 Feb, 2021 | 08:54h | UTCCommentary: Do statins cause muscle symptom side effects? – The BMJ Opinion AND Study: Muscle Symptoms Didn’t Differ Between Statin and Placebo Periods – NEJM Journal Watch
Related study: #AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo (study and commentaries)
Viewpoint: Placebo—the Unknown Variable in a Controlled Trial
23 Feb, 2021 | 01:16h | UTCPlacebo—the Unknown Variable in a Controlled Trial – JAMA Internal Medicine (free for a limited period)
Editorial: The reporting of race and ethnicity in medical and science journals
23 Feb, 2021 | 01:21h | UTCThe Reporting of Race and Ethnicity in Medical and Science Journals – JAMA
Guide to statistics and methods: Immortal time bias in observational studies
19 Feb, 2021 | 02:19h | UTCImmortal Time Bias in Observational Studies – JAMA (free for a limited period)
Commentary on Twitter
https://twitter.com/lucasmorin_eolc/status/1361966403985825792
What does 95% COVID-19 vaccine efficacy really mean?
19 Feb, 2021 | 02:58h | UTCWhat does 95% COVID-19 vaccine efficacy really mean? – The Lancet Infectious Diseases
Related: Pfizer vaccine: what an ‘efficacy rate above 90%’ really means – The Conversation
A food allergy epidemic… or just another case of overdiagnosis?
19 Feb, 2021 | 02:13h | UTCA food allergy epidemic… or just another case of overdiagnosis? – The BMJ Opinion
Original study: Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018 – The BMJ
EBM: “The sensitivity and specificity are lying to you”
9 Feb, 2021 | 01:01h | UTCThe sensitivity and specificity are lying to you – First10Em
Opinion: Peer reviewers—time for mass rebellion?
5 Feb, 2021 | 01:24h | UTCRichard Smith: Peer reviewers—time for mass rebellion? – The BMJ Opinion
5 things we learned about peer review in 2020
5 Feb, 2021 | 01:25h | UTC5 Things We Learned About Peer Review in 2020 – Absolutely Maybe
Decentralized clinical trials: Collaboration is needed to drive their adoption and impact
1 Feb, 2021 | 01:40h | UTCDecentralized clinical trials: Collaboration is needed to drive their adoption and impact – STAT
An analysis of contemporary oncology randomized clinical trials from low/middle-income vs. high-income countries
1 Feb, 2021 | 01:36h | UTCAn Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries – JAMA Oncology (free for a limited period)
Revised UNAIDS/WHO Ethical Guidance for HIV Prevention Trials
28 Jan, 2021 | 01:21h | UTCRevised UNAIDS/WHO Ethical Guidance for HIV Prevention Trials – JAMA